---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-151761"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2022-05-16T23:59:59+00:00"
generated_at: "2026-06-25T14:49:57.659220+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Acumen Q1 2022 net loss $9.1M; cash $216.7M, runway through 2025

## Summary
- Cash, cash equivalents and marketable securities totaled $216.7M as of March 31, 2022, down from $225.9M at year-end 2021; expected to fund operations through 2025.
- R&D expenses rose to $6.0M from $2.6M YoY due to ongoing Phase 1 trial (INTERCEPT-AD) of ACU193 for early Alzheimer's.
- Net loss was $9.1M vs $27.0M in Q1 2021; prior-year loss included $23.2M non-cash expense from warrant/liability fair value changes.
- Topline data from INTERCEPT-AD Phase 1 trial expected in first half of 2023; enrollment ongoing.
- Preclinical evidence supporting ACU193's selective targeting of soluble amyloid-beta oligomers published in Frontiers in Neuroscience.

## SEC filing metadata
- accession: 0001193125-22-151761
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2022-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000119312522151761/0001193125-22-151761-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000119312522151761/d357212d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-151761
- JSON: https://secwatch.observer/filing/0001193125-22-151761.json
- Plain text: https://secwatch.observer/filing/0001193125-22-151761.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.